UNIGE document Scientific Article
previous document  unige:33771  next document
add to browser collection
Title

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Authors
Templeton, Arnoud J
Cathomas, Richard
Rothermundt, Christian
Bärtschi, Daniela
Dröge, Cornelia
Borner, Markus
show hidden authors show all authors [1 - 20]
Published in European Urology. 2013, vol. 64, no. 1, p. 150-8
Abstract The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.
Identifiers
PMID: 23582881
Full text
Article (Published version) (1.9 MB) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Immunothérapie des cancers (42)
Citation
(ISO format)
TEMPLETON, Arnoud J et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). In: European Urology, 2013, vol. 64, n° 1, p. 150-8. https://archive-ouverte.unige.ch/unige:33771

127 hits

0 download

Update

Deposited on : 2014-01-28

Export document
Format :
Citation style :